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Abstract
Background: This study evaluated the clinical accuracy and analytical sensitivity of the NanoSign® Influenza A/B
antigen kit in detecting 2009 pandemic influenza A/H1N1 viruses. The kit is one of the most popular rapid
diagnostic tests for detecting influenza in Republic of Korea.
Results: The NanoSign® Influenza A/B kit resulted in 79.4% sensitivity and 97.2% specificity compared to RT-PCR in
the detection of the viruses from 1,023 specimens. In addition, the kit was able to detect two strains of novel
influenza viruses, Influenza A/California/12/2009(H1N1) and clinically isolated wild-type novel influenza A/H1N1,
both of which are spreading epidemically throughout the world. In addition, the correlation between NanoSign®
Influenza A/B test and conventional RT-PCR was approximately 94%, indicating a high concordance rate. Analytical
sensitivity of the kit was approximately 73 ± 3.65 ng/mL of the purified viral proteins and 1.13 ± 0.11
hemagglutination units for the cultured virus.
Conclusions: As the NanoSign® Influenza A/B kit showed relatively high sensitivity and specificity and the good
correlation with RT-PCR, it will be very useful in the early control of influenza infection and in helping physicians in
making early treatment decisions.
Background
The novel influenza A/H1N1 virus has spread to most
of the world’s populations, and its spread has led to a
pandemic alert situation [1-3]. As a result, at the end of
2009, the World Health Organization announced that
the novel influenza A/H1N1 had reached pandemic sta-
tus [4].
A variety of different diagnostic methods can be used
to detect the presence of influenza viruses in respiratory
specimens such as nasopharyngeal aspirates, including
direct antigen detection tests, virus isolation in cell
cultures, and detection of influenza-specific RNA by
real-time reverse transcriptase (RT)-polymerase chain
reaction (PCR) [5-10]. Albeit the gold standard for the
diagnosis of influenza is virus isolation using chicken
embryos or tissue culture method, it has the
shortcomings such as time consuming and labor inten-
siveness; it takes between two to 14 days before results
are available. Detection of virus-infected cells in naso-
pharyngeal secretions by direct or indirect immuno-
fluorescent staining is widely used, but it is a difficult
and technician-dependent technique still requiring two
hours to complete [11].
For the effective control and treatment of novel influ-
enza, rapid and cost-effective diagnosis is important.
Rapid diagnosis of influenza allows the physician to
begin antiviral treatment, thereby helping control noso-
comial transmission of the infection [12,13]. It also
helps reducing costs and hospital stay. Rapid diagnostic
tests (RDT), known as lateral flow rapid tests, have pre-
viously been shown to be cost-effective in pediatric
patients [14,15] and effective in controlling influenza
epidemics in geriatric institutions [12,16].
The NanoSign® Influenza A/B test is a rapid diagnostic
test, which detects the viraln u c l e o p r o t e i na n t i g e no f
influenza virus. This kit has been popularly used in
Korea and by Korean governmental organizations,
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tion (CDC), since its high accuracy has been demon-
strated, with a high sensitivity and specificity against
seasonal influenza A viruses, including A/H3N2, A/
H1N1 (seasonal) and H2N2 [17,18].
This study evaluated the clinical accuracy and analyti-
cal sensitivity of the NanoSign® Influenza A/B kit in
detecting novel influenza A/H1N1. Using two types of
novel influenza A/H1N1, A/California/12/2009(H1N1)
and clinically isolated wild type influenza A/H1N1, the
sensitivity and detection limits of the NanoSign® Influ-
enza A/B kit were evaluated in this study.
Results and Discussion
Clinical data
A total of 1,023 specimens were tested in this study.
Among the samples, 199 cases were confirmed to be
positive against novel influenza by conventional RT-PCR
assay. All specimens were subjected to NanoSign® Influ-
enza A/B test. As shown in Table 1, the kit resulted in
79.4% sensitivity and 97.2% specificity (p < 0.001). Sensi-
tivity was calculated by the number of positives recog-
nized by the kit divided by the number of positives
identified by RT-PCR assays, and expressed as a percen-
tage [19]. Similarly, the specificity was calculated by the
number of negatives recognized by the kit divided by
the number of negatives identified by RT-PCR assays,
and expressed as a percentage [19]. Table 2 showed a
more detailed presentation of the results for novel
influenza virus by institution, with either results of
NanoSign® Influenza A/B antigen kit or conventional
RT-PCR. Positive results seemed to be more frequently
observed in general hospitals than local ear-nose-and-
throat (ENT) clinics. This can be attributable to the cur-
rent Korean Flu Prevention & Control System. A person
with flu-like syndrome first admits a local ENT clinic
near home and if it turns out to be influenza infection
than the patient is referred to the general hospital for
confirming whether it is novel influenza A/H1N1 infec-
tion or not. Thus, a higher rate of positive tests for
novel influenza virus is an expected finding.
Values obtained by the NanoSign® Influenza A/B test
showed a considerably high accuracy in the detection of
novel influenza. Some studies have shown a very low
sensitivity (about 50%) using other RDT kits that are
predominantly used in the market, even though the kits
have a high accuracy for the detection of seasonal influ-
enza viruses [20,21]. In addition, the correlation between
NanoSign® Influenza A/B test and conventional RT-PCR
was approximately 94%, indicating a high concordance
rate.
Analytical sensitivity
To date, there are few studies on the analytical sensitiv-
ity of commercialized RDT kits for detecting novel
influenza viruses [9,22,23]. In this study, chicken
embryos were used to culture the novel influenza A/
California/12/2009(H1N1) and then the cultured viruses
were purified to homogeneity using density gradient
ultracentrifugation (Figure 1). Using the pure virus solu-
tion, the analytical sensitivity of NanoSign® Influenza A/
B was 73 ng/mL of the purified novel influenza viral
proteins (multiple testing revealed 5% deviation, ± 3.65
ng/mL) (Figure 1A). In addition, in the case of the wild
type novel influenza virus found in Korea, the sensitivity
was 1.13 ± 0.11 hemagglutination (HA) unit with possi-
bly about 10% deviation (Figure 1B). Several wild types
of novel influenza viruses have been tested for the
detection limit of the kit and all cut-off values were
within the range of 1 to 3 HA units.
Rapid influenza diagnostic tests are antigen-detection
tests that target the nucleoprotein of the virus. Usually,
the commercially available RDT kits provide results
within less than 30 minutes. Thus, results are available
in a clinically relevant time frame to help assist in the
clinical decision-making process, thereby preventing sec-
ondary infection. Some studies have reported that RDT
kits have a low to moderate sensitivity against novel
influenza compared to RT-PCR [24]. However, the ana-
lytical sensitivity of RDT kits is dependent on the prop-
erties of its antibody. According to this clinical
evaluation of the NanoSign® Influenza A/B antigen kit,
its sensitivity for novel influenza (79.4%) was signifi-
cantly higher than commercialized detection kits (10-
70%) that have been reported to the CDC [25]. There
are many factors that can affect the sensitivity of the
RDT kit, since, unlike RT-PCR, it does not have any tar-
get amplification step. Factors that contribute to the
sensitivity of the RDT include technician skill in collect-
ing specimens, the type of specimen, the quality of the
specimen, the stage of illness when the specimen was
collected, and patient age. In addition, the physician’s
Table 1 Performance of NanoSign® Influenza A/B Antigen kit for the detection of novel influenza A/H1N1
Results of conventional RT-PCR Total
Positive Negative
Results of NanoSign® Influenza A/B antigen kit Positive 158 23 181
Negative 41 801 842
Total 199 824 1,023
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obtaining higher sensitivity.
RDT kits such as the NanoSign® Influenza A/B antigen
kit are very useful in the early control of influenza infec-
tion and in helping physicians in making early treatment
decisions. However, the negative results of this particu-
lar RDT kit used in this study do not rule out influenza
virus infection because its sensitivity is not 100%. For
this reason, when there is a high clinical suspicion of
influenza infection in a patient, empirical antiviral ther-
apy should be administered. Finally, when reporting the
results of a RDT kit, it should be better to inform the
physicians about the limitations of the test, so that they
can decide the most effective clinical approach.
Conclusions
The NanoSign® Influenza A/B kit had 79.4% sensitivity
and 97.2% specificity in the detection of the viruses, and
could detect two strains of novel influenza viruses,
Influenza A/California/12/2009(H1N1) and wild-type
novel influenza A/H1N1. Analytical sensitivity of the kit
was approximately 73 ± 3.65 ng/mL for the purified
viral proteins and 1.13 ± 0.11 HA units for the cultured
virus. In addition, the correlation between the Nano-
Sign® Influenza A/B test and conventional RT-PCR was
94%, indicating a high concordance rate. The NanoSign®
Influenza A/B kit may be very useful in the early control
of influenza infection and in helping physicians in mak-
ing early treatment decisions.
Methods
Viruses
Influenza A/California/12/2009(H1N1) was kindly pro-
vided by the Laboratory of Virology, Chungbuk
National University and wild-type novel influenza A/
H1N1 was obtained from the Department of Labora-
tory Medicine, National Health Insurance Corporation
Ilsan Hospital.
Table 2 Detailed results for the detection of novel influenza viruses by institutions
Hospitals Results of NanoSign® Influenza A/B antigen kit/Results of conventional
RT-PCR
Ilsan Hospital
(Ilsan city), n = 170
93/120 48/50
Chungbuk National University Hospital (Cheongju city), n = 123 18/23 96/100
Local ENT Clinics
(Korean domestic), n = 730
47/56 657/674
Total, n = 1,023 158/199 801/824
Figure 1 Analytical sensitivity of NanoSign® Influenza A/B for novel influenza viruses. (A) The novel influenza A/California/12/2009(H1N1)
viruses were cultured in the fertilized chicken embryo, harvested from the allantoic fluid, and purified to homogeneity using density gradient
ultracentrifugation (3% sucrose), as described [26]. The purified viruses were serially diluted in 2-fold manner and tested with the RDT kit.
Bradford protein assay was used for the protein quantification. (B) The clinically isolated wild type novel influenza viruses were cultured in MDCK
cell line. When the cytopathic effect was observed, the cultured viruses were harvested. The viral stocks were serially diluted in 2-fold manner
and tested with the RDT kit. Hemagglutination assay was used for the titration of the viruses. w+, weak positive; CO, cut-off value.
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A host cell, MDCK, for the culture of the viruses from
nasal swabs and aspirates was kindly provided by the
laboratory of Professor Chan-Hee Lee. Chicken embryos
were purchased from an egg store in Korea (Ochang
Mart, Ochang, Republic of Korea).
Virus culture
For the culture of Influenza from the aspirates of nasal
swabs, MDCK cells were cultured in DMEM (Invitrogen
Corporation, Carlsbad, CA) supplemented with 5% fetal
bovine serum (FBS, Invitrogen Corporation) at 37°C and
5% CO2. Before infection, MDCK cells were trypsinized
in 1 × 10
7 cells per T75 flasks (Nalge Nunc Interna-
tional, Rochester, NY). After seeding in 10 mL DMEM
plus 5% FBS at 80-90% confluency, plated cells were
rinsed with phosphate-buffered saline (PBS, Invitrogen
Corporation). Suspended specimens in the flasks were
gently shaken for two hours for effective mixing. Cell
infections were observed until 80-90% of the cells were
floating or lightly attached to the T75 flask (typically 4-
5 days post-infection). At that time, harvesting and
storage of viral supernatant was performed.
Hemagglutination assay
The titer of the influenza A/H1N1 virus was determined
by HA assay. First, U-bottom 96 well plates (Nalge
Nunc International) were prepared and 50 μLo fP B S
(pH7.0) was added to each well. Next, after adding
50 μL of original viral solution, they underwent two
folds serial dilutions. Finally, 50 μLo f0 . 5 %t u r k e yr e d
blood cells were added and mixed. The mixture was
then incubated for approximately 30 minutes at room
temperature. The number of positive reactions showing
agglutination was observed and recorded to calculate
virus titer.
Immunochromatography assay
To prepare the nasal swab specimens, a sterile swab was
carefully inserted into the nostril with the most secre-
tions under visual inspection. Using a gentle rotation,
the swab was pushed until a weak resistance occurred at
the level of the turbinate (less than one inch into the
nostril). Next, the swab was rotated a few times against
the nasal wall. To test the RDT kit, a test strip was
inserted into the tube containing the 300 μLo fe x t r a c -
t i o ns o l u t i o na n da l l o w e dt os i ta tr o o mt e m p e r a t u r e
prior to testing. After preparing the nasal swab, the
sample was inserted into the tube and swirled at least
six times while pressing the head against the bottom
and side of the tube (the swab head should be rolled
and squeezed against the inside of the tube as it is
removed). Finally, the test strip was inserted into the
tube containing the sample-extracted solution. The
results were interpreted after 10 minutes. Some positive
results appeared sooner, but results were not read after
30 minutes.
Conventional RT-PCR
For confirmation of cultured influenza A/H1N1, the
viral RNA was isolated from the infected MDCK cells.
RT-PCR was performed with the commercialized Influ-
enza A(H1N1) Detection Kit by using primers targeting
the novel influenza (GeNet Bio, Nonsan, Republic of
Korea). RNA was directly extracted from the specimens
or virus cultured-supernatant using the QIAGEN® Viral
RNA mini kit (Qiagen, Hilden, Germany). cDNA synth-
esis was accomplished at 42°C for 30 minutes. Next, the
DNA was amplified by 40 cycles of PCR with three
steps: denaturation at 94°C for 20 seconds, annealing at
54°C for 20 seconds, and elongation at 72°C for 30 sec-
onds. Finally, an additional elongation step (72°C/5 min)
was carried out. The amplified gene products were ana-
lyzed with 2% agarose gel electrophoresis. The size of
the amplified target was 170 base pair for novel influ-
enza A/H1N1 and 350 base pair for seasonal influenza
A/H1N1.
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